References

1. Nolen, S. (2007). 28 stories of AIDS in Africa. Canada: Vintage Canada. [Return to page]
2. http://www.phac-aspc.gc.ca/aids-sida/populations-eng.php [Return to page]
3. http://data.unaids.org/pub/BaseDocument/2008/20080501_fastfacts_prevention_en.pdf [Return to page]
4. http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/page/E_HIV+and+AIDS?OpenDocument [Return to page]
5. http://www.avert.org/can-you-get-hiv-aids.htm [Return to page]
6. Dosekun, O. (2010). An overview of the relative risks of different sexual behaviours on HIV transmission. Current Opinion in HIV and AIDS,5(4),291-7. [Return to page]
7. http://www.who.int/hiv/topics/malecircumcision/en/ [Return to page]
8. British Columbia Centre for Excellence in HIV/AIDS. (1996). Protocols help protect against getting HIV – but you have to use them. Canada Communicable Diseases Report, 22(7), 54-59. [Return to page]
9. http://www.unaids.org/en/media/unaids/contentassets/dataimport/publications/external-documents/who_factsheets_nurses-midwives_en.pdf [Return to page]
10. www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.htm [Return to page]
11. http://www.avert.org/hiv-aids-transmission.htm#q22 [Return to page]
12. Gould, B.E. (2006). Pathophysiology for the health professions (3rd ed.). Philadelphia, PA: Elsevier Inc. [Return to page]
13. Major C. (2009). HIV ‘window period’ and new testing technologies: Implications for testing guidelines and programs to promote HIV testing in Ontario. Ontario HIV Treatment Network [Return to page]
14. http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf [Return to page]
15. http://www.avert.org/die.htm [Return to page]
16. Scripps Research Institute (2007). How Antibodies Fight HIV: New Evidence. ScienceDaily. Retrieved March 17, 2012, from http://www.sciencedaily.com­/releases/2007/09/070906132754.htm [Return to page]
17. http://www.avert.org/stages-hiv-aids.htm [Return to page]
18. Nolen, S. (2007). 28 stories of AIDS in Africa. Canada: Vintage Canada. [Return to page]
19. http://www.avert.org/hiv-types.htm [Return to page]
20. Mutchler et al. (2011). Community HIV treatment advocacy programs may support treatment adherence. AIDS Education and Prevention, 24(1). [Return to page]
21. http://www.catie.ca/en/practical-guides/practical-guide-hiv-drug-treatment-people-living-hiv [Return to page]
22. Mills E. et al. (2006). The challenges of involving traditional healers in HIV/AIDS care. International Journal of STD & AIDS, 17(6). [Return to page]
23. Mashta, O. (2009). WHO warns against using homeopathy to treat serious diseases. British Medical Journal, 339(b3447). [Return to page]
24. Eiznhamer D.A. et al. (2002). Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clinical Trials. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12501127 [Return to page]
25. http://home.ncifcrf.gov/mtdp/Catalog/abstract/abs172.html [Return to page]
26. Briz, V., Poveda, E., Soriano, V. (2006). HIV entry inhibitors: mechanisms of action and resistance pathways. Journal of Antimicrobial Chemotherapy, 57(4), 619-27. [Return to page]
27. Relf, M., Mekwa, J., Chasokela, C., et al. (2011). Journal of the Association of Nurses in AIDS Care, 22(1), S9-S16. [Return to page]